104 PD-1 Inhibition with Nivolumab Can Cure EBV-driven Lymphoproliferative Disorders, Avoiding Need for Toxic Allogeneic Bone Marrow Transplantation
Clinical Immunology（2024）
Key words
EBV,Lymphoproliferative disorder,HLH,Nivolumab,BMT,Pediatric and young adult
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined